Lung Cancer

2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLC

April 15, 2022

Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.

Adjuvant Pembrolizumab Reduces Recurrence Risk in Resectable NSCLC

March 25, 2022

Findings from the KEYNOTE-091 trial showed that patients with non–small cell lung cancer who were treated with pembrolizumab following complete resection and chemotherapy had a 24% decreased risk of recurrence compared with a control arm.